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Summary.-Growth of the Walker 256 carcinosarcoma implanted within various
sites in Sprague-Dawley rats was investigated in animals receiving twice daily i.p.
injections of the antiprotease aprotinin.
Although administration of aprotinin partially attenuated the growth and
lethality of i.p. tumour, no effect of aprotinin was found on intramuscular tumour
development. Furthermore, we were unable to demonstrate unequivocal growth
inhibition by aprotinin of lung tumour colonies from i.v. injection of tumour cells.
Histological examination of intramuscular and pulmonary tumours revealed little
evidence of host cellular immune response in either saline- or aprotinin-treated
rats.
ALTHOUGH the presence of proteases
within malignant invasive tumours is
well documented (Strauch, 1972; Wallach,
1975) the role of these enzymes in the
phenotypic expression of malignant tu-
mour cells has not been fully resolved
(Wallach, 1975).
There is evidence that proteases exert
a mitogenic effect on cultured cells (Bur-
ger, 1970; Sefton and Rubin, 1970) and
the activity of proteases at the cell
surface has been implicated as one of the
many factors regulating cell growth
(Hynes, 1976; Talmadge, Noonan and
Burger, 1974). The enhanced growth of
virally transformed cells relative to their
non-transformed homologues in vitro has
been causally related to elevated protease
activity ofthe transformed cells (Schnebli,
1974; Roblin, Chou and Black, 1975) and
it has been suggested that tumour cell
proteases not only potentiate the un-
restrained growth of malignant tumour
cells in vivo (Sylven, 1967; Bosmann and
Hall, 1974) but also play an important
role in tumour cell invasiveness (Strauch,
1972; Easty and Easty, 1976).
A number of protease inhibitors, in-
cluding synthetic reagents as well as
naturally occurring substances such as
aprotinin, exert growth inhibition of
malignant transformed cells in vitro (Lat-
ner, Longstaffand Pradhan, 1973; Roblin
et al., 1975). Aprotinin (Trasylol ®) is
a polyvalent inhibitor of the proteolytic
enzymes trypsin, chymotrypsin, plasmin
and the plasma kallikreins (Werle, 1970).
It has been claimed that aprotinin ad-
ministered by various routes not only
inhibits the growth and invasiveness of
solid tumours in mice and hamsters,
but also promotes lymphocyte infiltration
and necrosis within the tumour tissue
(Latner, Longstaff and Turner, 1974).
We have investigated whether aprotinin
could exert an anti-tumour effect against
a transplantable rat carcinosarcoma in-
jected by different routes, and have
examined the histopathology of tumours
in aprotinin- and saline-treated rats andAPROTININ AND TUMOUR GROWTH
compared the degree of necrosis and
host lymphoid cell infiltration in each
case.
MATERIALS AND METHODS
Aprotinin was supplied as a solution
(1.5 mg/ml, in 0-9o w/v aqueous NaCI)
as Trasylol g, by Bayer Pharmaceuticals
Ltd., Haywards Heath, Sussex, England.
Due to its short half-life in serum (Werle,
1970) aprotinin was administered systemically
twice daily by the i.p. route in preference
to the i.v. route, since thrombophlebitic
reactions may occur with repeated vene-
puncture (Bayer Pharmaceuticals).
Studies on tumour development were
performed using male Sprague-Dawley rats,
250-300 g, bred in the Animal Department,
University Medical Buildings, Foresterhill,
Aberdeen, and receiving a commercial diet
and tap water ad libitum. Walker 256
carcinosarcoma cells were obtained from
8-day intramuscular tumours routinely trans-
planted in Sprague-Dawley rats. Tissue
was gently disrupted through 80-mesh stain-
less steel gauze using Eagle's minimal
essential medium (Wellcome Laboratories
Ltd) and cell viability was estimated by
trypan blue dye exclusion. Rats received
5 X 106 viable tumour cells i.m. (in 0 5 ml)
or 106 either i.p. (0.5 ml) or i.v. (0-2 ml
via the dorsal vein ofthe hind paw). During
injection, cell suspensions were kept on
ice and aspirated every 5-10 min to prevent
cell aggregation.
Monitoring of tumour development.-I.p.
growth of tumour was assessed by scoring
the number of surviving rats in each group
at a fixed time each day after injection of
tumour cells. After i.m. injection, 3 dia-
meters (X, Y, Z) ofthe muscle were measured
on Days 4, 6 and 8 to an accuracy of 0 1 mm
using precision calipers (Ultratek Ltd.,
Japan). An estimation of muscle volume
was obtained using the formula XYZ -7/6.
At 7 days after i.v. injection of tumour
cells, lungs were removed and inflated
via the trachea, using 10% v/v neutral
buffered formalin. Sections of paraffin-em-
bedded tissue were cut 5-,um thick at 4
levels, 200 ,um apart, for each lung, mounted
on 2 x 2 glass slides, and stained with
haematoxylin and eosin. The tumour colo-
nies within each lung section were counted
on projected images of each specimen, and
the presence of tumour cells within these
colonies confirmed by light microscopy.
Histological examination of i.m. tumour
tissue.-The extent of tumour cell necrosis
and the incidence of host cells were assessed
by inspection of coded stained (H and E)
sections of tumour tissue obtained at 8 days.
The degree of necrosis and of host leucocyte
infiltration were scored on an arbitrary
+ to ++++ basis (++++ being
equivalent to 90Y necrosis).
RESULTS
The effect of twice daily i.p. injections
of 2 ml aprotinin on survival of rats
at various times after i.p. challenge
with tumour cells is shown in Fig. 1.
There were fewer deaths in the aprotinin-
treated group from Days 6 to 11 after
tumour injection. However, by Day 12
only one rat survived in both saline- and
aprotinin-treated groups.
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FIG. 1. Survival of Sprague-Dawley rats at
different times after i.p. injection ofWalker
carcirnosarcoma cells; open columns, saline-
treated; closed columns, aprotinin-treated.
The results of monitoring tumour
growth in rats receiving cells i.m. are
shown in Table I. Animals received 2 ml
aprotinin twice daily from the time of
tumour challenge (Day 0) or from Day 3.
Controls received an equivalent volume
of saline twice daily from Day 0. There
was no significant difference in the size
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TABLE I. Intramu,scular Development of Walker 256 Carcinosarcorna
Treatment
Saline
Aprotinin from Day 0
Aprotinin fIom Day 3
Day after tumour cell injection
Mluscle dliametei r A
(mm) 4 6 8
X 21 1±3 7 25 9+3 5 29 0± 65
Y 27 4±4 9 28 7+6 9 32 7±6 4
Z 35-114-2 34-2±7-8 36-7 4-6
volume (cm3) 1l3-52 14 4±7 6 19 2±9 1
x
y
z
VolUme (Cm3)
21 3± 3 5
27-6-L-4 2
35 0± 3 5
11.31-4.8*
X 204 4±43
Y 27 0±5 7
z 33 5±2 3
Voltme (Cm3) 9.9±4.4*
25 2 9
28 35 58
335± 4 9
13 415.7*
26 2±3 3
29 6±6 8
33 5+7 8
147 7.79*
27 5±7 5
30-1 4-44
35 0 449
19.4±9.7*
31 1±6 ± 0
33.9± 7 9
38 226-6 13
22 9+-t12 8*
The values are mean ± S.1. of the results obtaine(d from 20 rats.
* Values niot significantly (liffeIrent by Stuicients' t test from correspon(ding values in saline-treated
gl'olup.
TABLE II. Histopathology of Intramuscular Tumours
Saline
Tumour
necrosis PMN
-++ ++
-4F
+
+ + +
+,+i
+
++-I
+ +
L
+i
Aprotinini from Day 0
Tumoui
M necrosis PMNI L AI
NT
+ + + .- +
NT
+FI
+ + 7-
Aprotinini fiom Day 3
Tuimour
niecIo-sis PMlN L M
++ 1 + ±+
,,
+ + T +
+ +
+ i++
+ +
A-+
PMN = polymorphonticlear leutcocytes
L = lymphocytes
M = macrophages
NT = nio tumour
of tumours between saline- and aprotinin-
treated groups at either 4, 6 or 8 days
after injection of the carcinosarcoma
cells. Furthermore, when compared his-
tologically, the degrees of tumour cell
necrosis and infiltration of leucocytes
were comparable in the three treatment
groups (Table II). There was no dif-
ference in the character of the host cell
infiltrate between groups, the prominence
of host inflammatory cells (polymorphs,
lymphocytes and macrophages) within the
tumours being comparable in saline and
aprotinin treatments.
The incidence of pulmonary tumour
colonies in saline- and aprotinin-treated
groups of rats is shown in Fig. 2. Al-
though little variation was found in
the number of colonies from section to
section in any one lung and between
lungs in the same rat, there was some
variability in the number of colonies per
lung section between animals. In this
study, 3 groups of 12 rats were used and
they received either aprotinin or saline
as described above. A decrease in the
incidence of colonies was obtained when
aprotinin was first given at the time of
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tumour cell injection. However, when
aprotinin was first injected 3 days after
tumour cells,`3 out of 12 rats had many
more colonies than the saline controls.
DISCUSSION
The role of proteases in the growth
of malignant tumours is multifaceted.
First, proteolytic activity at the cell
surface may stimulate cell growth (Hynes,
1976; Talmadge et al., 1974). Within
some tumour' tissues there is elevated
activity of certain proteases, in particular
the lysosomal-eatheptic enzymes (Sylv6n,
1967; Bosmami and Hall, 1974) and
collagenase (Dresden, Heilman and
Schmidt, 1972; Strauch, 1972) and it
has been postulated that elevated pro-
teolytic activity may be causally related
not only to loss of control of cell growth
(Burger, 1973) but also decreased mutual
adhesiveness, metastasis and invasiveness
of malignant tumour cells (Easty and
Easty, 1976).
Second, there is a general association
between neoplasia and fibinolysis, the
fibrinolytic activity being responsible for
dissolution of fibrinogen and fibrin within
tumour tissue (Reich, 1973). Malignant
tumour cells initiate fibrinolysis by re-
leasing serine protease(s) (" plasminogen
activator(s) "), which convert plasminogen
to the fibrinolytic protease plasmin
(Davidson et al., 1969; Bjorlin, Pandolfi
and Astedt, 1972; Reich, 1974). In addi-
tion to its fibrinolysis, plasmin is also
involved in the conversion of serum
kininogens to vasoactive kinins (Back,
1966; Burrowes, Movat and Soltay, 1972)
which may function in tumour growth
through a pharmacological influence on
the tumour vascular supply (Cater and
Taylor, 1966; Back, 1966).
Third, it has been suggested that
proteases may impair the immune re-
sponse of the tumour-bearing host by
destruction ofhistocompatibility antigens
on the tumour cell surface (Wallach,
1975) or by removal of specific receptors
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FIG. 2.-Incidence of tumour colonies in the
lungs of aprotinin-treated rats.
from antigen-reactive Tlymphocytes (Lat-
ner, Longstaff and Turner, 1974).
In view of the role of proteases in
malignant tumour growth outlined above
it might be anticipated that administra-
tion of antiproteases to tumour-bearing
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hosts would be a rational approach to
chemotherapy. However, previous in-
vestigations on the effects ofantiproteases
on tumour growth in vivo have provided
conflicting results.
In the present study, i.p. injection
of aprotinin attenuated tumour growth
as measured by lethality after i.p. in-
jection of tumour cells, for up to 12 days
after cell challenge. However, we have
been unable to demonstrate impairment
of growth of tumour cells inoculated
by the i.m. route after i.p. injection of
aprotinin. Furthermore, we have not
been able unequivocally to demonstrate
attenuation of development of pulmonary
tumours following i.v. injection ofWalker
carcinosarcoma cells.
Several studies have failed to demon-
strate tumour growth retardation in vivo
with protease inhibitors (Peterson, 1968;
Boeryd, 1965, 1966; Hagmar, 1970). In
fact, enhanced tumour metastasis and
growth have been observed following
administration of the protease inhibitors
tranexamic acid and e-aminocaproic acid
(Peterson, 1968; Gillette, Findley and
Conway, 1963). However, in the latter
studies the investigators considered it
more likely that the observed tumour
growth enhancement was attributable
to an immunosuppressive effect of these
reagents rather than their antiprotease
function.
As a result ofits binding to ubiquitous
sialyl moities, aprotinin may be seques-
tered by many types of tissue cells
(Kiernan and Stoddart, 1973; Pugh-
Humphreys and Thomson, in preparation)
and therefore its potential effectiveness
as an antitumour agent may well be
limited by both its concentration and
activity within the vicinity ofthe tumour,
after its systemic administration. Con-
tinued infusion of aprotinin, which would
ultimately lead to saturation of binding
sites, might circumvent this limitation.
The increased incidence of experi-
mental pulmonary metastases observed
by Cliffton and Agostino (1964) in apro-
tinin-treated rats injected i.v. withWalker
256 carcinosarcoma cells may be explained
by the known ability of aprotinin to
inhibit fibrinolysis (Cliffton and Agostino,
1964; Amris, 1966), since fibrin deposition
promotes lodgement of Walker 256 cells
within the pulmonary capillary network
(Chew, Josephson and Wallace, 1976).
In terms of the number of lung tumour
colonies produced in aprotinin- and saline-
treated rats, we observed two effects
ofaprotinin on tumour growth, depending
upon the relative timing of the injection
of aprotinin and tumour cells. Injection
of tumour cells, followed by immediate
andthentwice-dailyinjection ofaprotinin,
resulted in a significant decrease in the
incidence of lung colony development,
and these results contrast with those
presented by Cliffton and Agostino (1964).
In the light of the potentiating effects
of proteases on tumour cell growth
(Hynes, 1976; Talmadge, Noonan and
Burger, 1974), our results can be rational-
ized in terms of an inhibition of tumour-
cell protease, culminating in impaired
tumour cellgrowth. Only when aprotinin
was first administered 3 days after i.v.
inoculation oftumour cells did we observe
an increase in the numbers of lung
tumour colonies.
From our observations on the histo-
pathology of both the solid intramuscular
tumours and the lung tumour colonies,
we have been unable to demonstrate
a decrease in tumour invasiveness or
an effect on the intensity and character
of the host lymphoid cell infiltrate, in
aprotinin-treated animals. In addition,
we found no evidence that aprotinin
administration enhanced tumour necrosis.
These findings are in apparent conflict
with those of Latner, Longstaff and
Turner (1974), who reported that the
invasiveness and viability of a trans-
plantable murine adenocarcinoma and
a hamster fibrosarcoma were impaired
by aprotinin, and who also found an
increased host lymphoid infiltrate in
tumours in aprotinin-treated tumour-
bearing hosts. In a more recent paper,
Latner and Turner (1976) have provided
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evidence that the reported anti-tumour
effect of aprotinin is mediated via the
host immune response to the tumour.
However, with the highly malignant,
rapidly growing Walker 256 carcino-
sarcoma in Sprague-Dawley rats, we
have been unable to show histologically
that there is a marked host reaction
against the tumour. It would therefore
seem that under the conditions of our
experiments, where there is little evidence
of tumour immunogenicity, aprotinin is
not an effective anti-tumour agent.
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